OMIM 176270) is a relatively common (prevalence 1/15 0001/30 000) generally sporadic disorder with a recognizable pattern of dysmorphic features and major neurologic, cognitive, endocrine and behavioral/psychiatric disturbances
Everyone, it seems, is titrating somethingchasing sleep, calm, sharpness, sobriety, a longer lifein doses too small to be the labeled use, but also not precisely illegal or dangerous
(2025) NICE [accessed 15 January 2026]
**Conclusion:** Based on the current lack of safety data, Tirzepatide (Zepbound) is **generally not recommended for weight loss while breastfeeding.** If you are postpartum and *not* breastfeeding, using Zepbound is a possibility *only if* you meet the standard FDA eligibility criteria and have adequately recovered from childbirth